Back

RESEARCH PLATFORM 2

R.P 2.3 Developing Next-Generation Therapeutic Agents for Glaucoma

Principle Investigators

PolyU

Prof. Chi-wai DO

Prof. Chuen Thomas LAM

UWaterloo

Prof. Emmanuel HO

Co-I

Dr. Jingfang Jennifer BIAN

Prof. Simon, Ming-yuen LEE

Dr. Benqin TANG

Prof. Yan-yin Dennis TSE

Prof. Man-sau WONG

Prof. Ka-hing WONG

Prof. Qian ZHAO

Prof. Feng PAN

Dr. Li PAN

Overview

Glaucoma is the leading cause of irreversible blindness worldwide, characterized by raised intraocular pressure (IOP). Addressing the limitations of existing treatments, the study focuses on developing novel interventions that not only lower intraocular pressure but also provide neuroprotective benefits. Research activities include advancing a flavonoid-based therapy with dual efficacy, developing a dietary supplement formulation incorporating patented plant extracts, and optimizing a traditional Chinese medicine–based prescription through collaboration with specialized drug development partners. Together, these approaches explore diverse and complementary treatment pathways for glaucoma management.

Learn more about R.P 2.2 Learn more about R.P 2.4

R.P 1.1 Development and Clinical Validation of AI-Based Software as a Medical Device for Non-Invasive Ophthalmic Imaging and Automated Reporting

Development and Clinical Validation of AI-Based Software as a Medical Device for Non-Invasive Ophthalmic Imaging and Automated Reporting

R.P 1.2 Anti-Myopia Electronic Displays: Making Screens Eye-Safe for Children

R.P 1.3 Advanced Technologies for Prediction of Myopia Progression

R.P 1.4 Targeting Higher-Level Brain Functions for Amblyopia Rehabilitation

R.P 1.5 Novel Neuromodulation Approaches for Vision Enhancement in Adults

R.P 2.1 Clinical Translation of a Novel Anti-Microbial Therapy for Eye Infections

R.P 2.2 An Organoid Platform and Cell-Based Platform for Ocular Therapeutic Development

R.P 2.4 Novel Gene Delivery Platforms for the Treatment of Ocular Disease

R.P 2.5 Integrated Dry Eye Diagnosis and Precision Therapies

R.P 2.6 Development of Ocular Inserts and Aptamer-Based Delivery Vehicles for Sustained Release of Ocular Therapeutics and TCM Products

R.P 3.1 Eye Disease Diagnosis and Treatment Enabled by Novel Retinal Instrumentation

R.P 3.2 Non-Invasive Tear-Based Diagnostic System

R.P 3.3 Development of New-Generation Contact Lenses Using Novel Materials and Additive Manufacturing

R.P 3.4 Detection of Macular Degeneration and Myopia-Induced Retinal Damage Using Structured Light Technology

R.P 3.5 Extended Reality Visual Intelligence System (XRVIS) for Tele-Visual Assessment and Safety Enhancement for People with Visual Impairment

ENQUIRY